2008
DOI: 10.1007/s00277-008-0633-2
|View full text |Cite
|
Sign up to set email alerts
|

Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0
1

Year Published

2010
2010
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(8 citation statements)
references
References 22 publications
0
7
0
1
Order By: Relevance
“…Lovastatin was also shown to dampen in a heterogenous manner the primitive subfraction of CD34 + AML cells. 39 CD34 + AML cells that poorly responded in vitro identified a subgroup of AML patients with poor prognosis. 39 …”
Section: Manipulating Cholesterol Homeostasis In Hematopoietic Malign...mentioning
confidence: 99%
“…Lovastatin was also shown to dampen in a heterogenous manner the primitive subfraction of CD34 + AML cells. 39 CD34 + AML cells that poorly responded in vitro identified a subgroup of AML patients with poor prognosis. 39 …”
Section: Manipulating Cholesterol Homeostasis In Hematopoietic Malign...mentioning
confidence: 99%
“…The effect of statins on AML cell survival has been predominantly studied using AML cell lines that do not completely recapitulate the disease and that poorly reflect the genetic heterogeneity of AML. Studies exploring the impact of statins on primary AML cells show a heterogeneity of responses 5,6 and a possible association between poor prognosis and reduced statin sensitivity 5 . To improve AML treatment outcome, addition of pravastatin to standard induction chemotherapy has been explored, and results of a phase I study were encouraging 7 .…”
Section: Introductionmentioning
confidence: 99%
“…Studies exploring the impact of statins on primary AML cells show a heterogeneity of responses 5,6 and a possible association between poor prognosis and reduced statin sensitivity. 5 To improve AML treatment outcomes, addition of pravastatin to standard induction chemotherapy has been explored, and results of a phase 1 study are encouraging. 7 A phase 2 study of idarubicin and cytarabine in combination with pravastatin reported an increased complete response rate for relapsed AML 8 and improved outcomes for patients with unfavorable prognosis.…”
Section: Introductionmentioning
confidence: 99%
“…AML is considered to be initiated by unchecked growth of immature cells as a result of accumulated mutations. Recent studies suggest that leukemic cells are heterogenous and their biological functions are diverse among the population [13]- [16]. For example, AML CD34 + cells exhibited more resistance to apoptosis than CD34fractions [13].…”
Section: Introductionmentioning
confidence: 99%
“…CD34 + CD38leukemia progenitors had increased chemotherapy resistance, decreased immunogenicity and dendritic cell transformation capacities compared to CD34 + CD38 + cells [15]. The primitive CD34 + cells displayed higher sensitivity to the cholesterol synthesis inhibitor lovastatin than CD34cells [16]. However, the underlying mechanisms are still not fully understood.…”
Section: Introductionmentioning
confidence: 99%